Insider Selling: Amarin Co. plc (AMRN) Director Sells 140,416 Shares of Stock

Amarin Co. plc (NASDAQ:AMRN) Director Lars Ekman sold 140,416 shares of Amarin stock in a transaction dated Thursday, January 10th. The shares were sold at an average price of $17.28, for a total value of $2,426,388.48. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Amarin stock opened at $18.00 on Friday. The company has a market capitalization of $4.85 billion, a P/E ratio of -72.00 and a beta of 1.11. Amarin Co. plc has a one year low of $2.35 and a one year high of $23.33.

Amarin (NASDAQ:AMRN) last posted its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.01. The company had revenue of $55.00 million during the quarter, compared to analyst estimates of $60.63 million. Amarin’s revenue was up 16.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.04) earnings per share. Analysts predict that Amarin Co. plc will post -0.38 EPS for the current year.



A number of brokerages have recently commented on AMRN. BidaskClub raised Amarin from a “sell” rating to a “hold” rating in a research note on Monday, September 24th. HC Wainwright reissued a “positive” rating and set a $31.00 price target on shares of Amarin in a research note on Friday, November 2nd. Cantor Fitzgerald reissued a “buy” rating and set a $35.00 price target on shares of Amarin in a research note on Friday, December 7th. Citigroup reissued a “buy” rating and set a $25.00 price target (up from $17.00) on shares of Amarin in a research note on Tuesday, October 16th. Finally, SunTrust Banks lifted their price target on Amarin to $30.00 and gave the company a “reduce” rating in a research note on Monday, November 5th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $33.20.

Several institutional investors have recently bought and sold shares of AMRN. GSA Capital Partners LLP lifted its stake in shares of Amarin by 66.3% in the second quarter. GSA Capital Partners LLP now owns 162,800 shares of the biopharmaceutical company’s stock worth $503,000 after acquiring an additional 64,900 shares during the period. BlackRock Inc. lifted its stake in shares of Amarin by 1.4% in the second quarter. BlackRock Inc. now owns 3,392,430 shares of the biopharmaceutical company’s stock worth $10,482,000 after acquiring an additional 46,957 shares during the period. FMR LLC lifted its stake in shares of Amarin by 57.7% in the second quarter. FMR LLC now owns 5,335,221 shares of the biopharmaceutical company’s stock worth $16,486,000 after acquiring an additional 1,952,118 shares during the period. Northern Trust Corp lifted its stake in shares of Amarin by 20.9% in the second quarter. Northern Trust Corp now owns 113,327 shares of the biopharmaceutical company’s stock worth $350,000 after acquiring an additional 19,590 shares during the period. Finally, State of New Jersey Common Pension Fund D acquired a new position in shares of Amarin in the third quarter worth approximately $3,254,000. 42.94% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Amarin Co. plc (AMRN) Director Sells 140,416 Shares of Stock” was first published by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://dakotafinancialnews.com/2019/01/12/insider-selling-amarin-co-plc-amrn-director-sells-140416-shares-of-stock.html.

About Amarin

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Featured Article: What is the Rule of 72?

Insider Buying and Selling by Quarter for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply